Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Reps Will Shift To Vaccines In Second Half Of 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck expects to redeploy its Vioxx sales force to vaccines in the second half of 2005, the company said Dec. 14 during its annual business review in Whitehouse Station, N.J

You may also be interested in...



Merck Raises Zocor Projections For 2005 Due To Less Than Expected Competition

Merck believes Zocor (simvastatin) will perform better than initially projected in 2005 based mostly on less than expected competition in the market

Merck Raises Zocor Projections For 2005 Due To Less Than Expected Competition

Merck believes Zocor (simvastatin) will perform better than initially projected in 2005 based mostly on less than expected competition in the market

Merck Files ProQuad MMR/Varicella Combo Pediatric Vaccine

Company expects action on the BLA for a combination of its M-M-R II and Varivax vaccines by "early July" 2005. Three additional Merck vaccines are slated for submission over the next year, including agents for HPV and shingles.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel